Literature DB >> 8906804

Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis.

S Fournel1, L Genestier, E Robinet, M Flacher, J P Revillard.   

Abstract

The interaction between Fas ligand and Fas, both expressed on activated T cells, is the major pathway in the regulation of activation-induced cell death. However, activated T cells that express membrane Fas are initially resistant to anti-Fas-induced apoptosis and become susceptible only after proliferation in vitro. Since IL-2 is known to regulate activation-induced cell death, we studied the effect of IL-2 on anti-Fas-mediated apoptosis. Interference with the IL-2 pathway was achieved by 1) inhibition of cytokine synthesis using cyclosporin A or FK506, 2) neutralization of IL-2 by anti-IL-2 Ab, 3) inhibition of binding to IL-2R by CD25 mAb, and 4) blocking of IL-2R signaling by rapamycin. We show that Fas expression is independent of the IL-2 pathway, whereas Fas-mediated apoptosis does not develop in the presence of inhibitors of IL-2 production or signaling. While the addition of rIL-2 reversed the inhibitory effect of cyclosporin A and FK506, the addition of rIL-4, rIL-7, or rIFN-gamma did not, although these cytokines induced progression into the S phase of the cell cycle. Aphidicolin-treated activated T cells that do not progress into the S phase were susceptible to Fas-mediated apoptosis. Therefore, Fas-mediated apoptosis is controlled by signals generated by IL-2 in agreement with the reported alteration of apoptosis in mice deficient in IL-2 or IL-2R.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906804

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

Review 2.  The role of CD4 in regulating homeostasis of T helper cells.

Authors:  Rolf König; Xiaoli Shen; Rosario Maroto; Timothy L Denning
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  The characterization of testicular cell (TC)-specific T-cell clones induced by intratesticular Listeria monocytogenes infection: TC-specific T cells with atypical cytokine profile transfer orchitis.

Authors:  G Matsuzaki; K H Sonoda; A Mukasa; H Yamada; T Nakamura; H Ikebe; S Hamano; K Nomoto
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

4.  Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation.

Authors:  Andrés Norambuena; Claudia Metz; Lucas Vicuña; Antonia Silva; Evelyn Pardo; Claudia Oyanadel; Loreto Massardo; Alfonso González; Andrea Soza
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

Review 5.  Systemic lupus erythematosus and apoptosis: a question of balance.

Authors:  Dror Mevorach
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

6.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.

Authors:  L Genestier; R Paillot; S Fournel; C Ferraro; P Miossec; J P Revillard
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

7.  Caspase-dependent Cdk activity is a requisite effector of apoptotic death events.

Authors:  K J Harvey; D Lukovic; D S Ucker
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

8.  Smyd1C Mediates CD8 T Cell Death via Regulation of Bcl2-Mediated Restriction of outer Mitochondrial Membrane Integrity.

Authors:  Hui Nie; Gary Rathbun; Haley Tucker
Journal:  J Cell Signal       Date:  2017-09-12

9.  A novel noninvasive method to detect rejection after heart transplantation.

Authors:  Jun Hu; Xin Xie; Yuan Li; Shuang Wang; Qing Feng; Xin Wang; Daoyan Liang
Journal:  Braz J Med Biol Res       Date:  2012-10-16       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.